Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abercrombie & Fitch Co. (ANF) vs Axogen Inc (AXGN) Price & Performance

Abercrombie & Fitch Co.Trade
Axogen IncTrade

Price performance (Past 24H)

Key statistics

Abercrombie & Fitch Co. vs Axogen Inc — how do they compare? Abercrombie & Fitch Co. trades at $118.27 (market cap $5.24B), while Axogen Inc trades at $49.66 (market cap $2.61B). The key difference: Abercrombie & Fitch Co. is far larger — about 2× Axogen Inc's market cap, and Axogen Inc is trading nearer its 52-week high, Abercrombie & Fitch Co. nearer its low. Which is the better fit depends on your goals.

ANFAXGN
Market Cap
$5.24B$2.61B
Sector
Consumer CyclicalTechnology
52-Week High
$129.85$48.48
52-Week Low
$65.61$14.16
Enterprise Value
$5.91B$2.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abercrombie & Fitch Co.

ANF trades at $113.06, down 4.61% on the day, but maintains strong fundamentals with a P/E of 11.41 and robust profitability margins. The stock exhibits a bullish technical trend with moving averages supporting upside, though oscillators signal overbought conditions. Recent earnings beats and a return to positive cash flow in 2026 highlight operational strength, while institutional interest grows, as seen with Amundi's increased stake in Q2 2026.

Outlook remains positive driven by earnings momentum and valuation appeal, but risks include Hollister brand headwinds and geopolitical tensions affecting EMEA growth. Analyst consensus leans bullish with a $112.86 price target, suggesting limited upside from current levels amid near-term volatility.

Axogen Inc

AXGN trades at $49.10, up 1.82% with strong technical momentum and bullish analyst sentiment. The stock shows robust revenue growth (23.1% in Q2 2026) and raised full-year guidance to $279 million, though profitability remains negative with a -13.36% net margin. Technical indicators show overbought RSI levels but strong moving average support, while institutional ownership and analyst consensus (84% buy ratings) signal confidence in the company's nerve care platform expansion.

The outlook remains positive given strong revenue momentum and regulatory advantages, but investors face execution risks from persistent losses and high valuation multiples. Upside potential exists toward the $54.33 consensus target if margin improvements materialize, though volatility may persist near current resistance levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abercrombie & Fitch Co.

Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.

Read more on ANF

About Axogen Inc

Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.

Read more on AXGN